A Significant Commercial Opportunity

Novel antibiotics are worryingly undervalued compared to treatments for other disease areas despite the rapid emergence of new multi-drug resistant bacteria with near term mortality rates of 30-50 percent in blood infections.

Increasing prevalence of resistance is likely to be matched by rising prices for innovative antibiotics.

Helperby’s renewable approach, using multiple ARBs with each antibiotic, can create a sustainable and commercially viable long term solution in high value markets.

HY-001 – Complicated Urinary Tract Infections (cUTI)

  • By 2020, it is estimated there will be approx. 4 million cUTIs patients each year in the US and Europe, with over 55,000 cases estimated to be resistant to carbapenems *
  • Target launch date: 2020

HY-002 – Intra-Abdominal Infections (IAI)

  • By 2022, it is estimated there will be approx. 0.8m IAIs patients each year in the US and Europe, with over 15,000 cases resistant to carbapenems *
  • Target launch date: 2022

HY-004 – Nosocomial MRSA

  • An estimated 1m+ patients in the US and Europe would be eligible for treatment with this product as a prophylactic if it were available in 2017 *
  • Projected launch date: 2022

HY-005 – Skin & Soft Tissue MRSA

  • Approx 10m hospital cases in the US and Europe each year to date *
  • Projected launch date: 2023

HY-006 – Cystic Fibrosis

  • Affects approx. 70,000 people worldwide **
  • Projected launch date: 2024

HY-007: Halitosis

  • Halitosis has a worldwide occurrence with a prevalence range of 22-50% and serious social & psychological effects ***
  • Market ready

* Akesios Associates Research 2017
** Cystic Fibrosis Foundation Patient Registry 2017
*** Oral Health Prev Dent. 2014;12(4):297-304. doi: 10.3290/j.ohpd.a33135

Partnering with Helperby

Interested in exporing the market opportunity offered by Helperby Therapeutics?

Partner With Helperby